SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Betagan 0.5% w/v Unit Dose Eye Drops, Solution

2    QUALITATIVE AND QUANTITATIVE COMPOSITION

One ml solution contains 5.0 mg levobunolol hydrochloride, equivalent to 4.4 mg levobunolol.

For a full list of excipients, see section 6.1.

3    PHARMACEUTICAL FORM

Eye Drops, solution.

A clear, colourless to brown solution.

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

Reduction of intraocular pressure in chronic open-angle glaucoma and ocular hypertension.

4.2    Posology and method of administration

Posology

Adults (including the elderly)

The recommended adult dose is one drop of Betagan once or twice daily in the affected eye(s). Discard product after use.

Paediatric Population

Betagan is not recommended for use in children due to lack of safety and efficacy data.

Intraocular pressure should be measured approximately four weeks after starting treatment with Betagan as a return to normal ocular pressure can take a few weeks.

Method of administration: topical into the conjunctival sac.

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Reactive airway disease including bronchial asthma or a history of bronchial asthma or severe chronic obstructive pulmonary disease

Sinus bradycardia, sick sinus syndrome, sino-atrial block, second and third degree atrioventricular block not controlled with a pace maker, overt cardiac failure or cardiogenic shock.

4.4 Special warnings and precautions for use

Like other topically applied ophthalmic agents, levobunolol is absorbed systemically. Due to the beta-adrenergic component of Betagan (levobunolol), the same types of cardiovascular, pulmonary and adverse reactions as seen with systemic beta-blockers may occur. Incidence of systemic ADRs after topical ophthalmic administration are lower than for systemic administration. To reduce the systemic absorption, see 4.2.

Cardiac disorders: In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.

Due to their negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree atrioventricular block.

Vascular disorders: Patients with severe peripheral circulatory disturbance disorders (i.e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution.

Respiratory disorders: Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of levobunolol.

Betagan should be used with caution in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.

Hypoglycaemia/diabetes: Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes as beta-blockers may mask the signs and symptoms of acute hypoglycaemia.

Beta-blockers may also mask the signs of hyperthyroidism

Corneal diseases: Ophthalmic P-blockers may induce dryness of eyes.

Patients with corneal diseases should be treated with caution.

Other beta-blocking agents: The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be exaggerated when levobunolol is given to patients already receiving a systemic beta blocking agent. The response of these patients should be closely observed. The use of two topical beta-adrenergic blocking agents is not recommended (see section 4.5).

Anaphylactic Reactions: While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.

Choroidal detachment: Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.

Surgical anaesthesia: P-blocking ophthalmological preparations may block systemic P-agonist effects e.g. of adrenaline. The anaesthetist must be informed when the patient is receiving levobunolol.

4.5 Interaction with other medicinal products and other forms of interaction

No specific drug interaction studies have been performed with levobunolol.

There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blocker solutions are administered concomitantly with oral calcium channel blockers, beta-adrenergic blocking agents, anti-arrhythmics (including amiodarone), digitalis glycosides or parasympathomimetics or guanethidine.

Mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate data for the use of levobunolol in pregnant women. levobunolol should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see 4.2.

Epidemiological studies have not revealed malformative effects but show a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If Betagan is administered until delivery, the neonate should be carefully monitored during the first days of life. Animal studies with levobunolol have shown reproductive toxicity at doses significantly higher than would be used in clinical practice.

Breast-feeding

Beta-blockers are excreted in breast milk. However, at therapeutic doses of levobunolol in eye drops, it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant. To reduce the systemic absorption, see 4.2.

If treatment with levobunolol during lactation is considered necessary for the benefit of the mother, consideration should be given to the cessation of breast feeding.

4.7 Effects on ability to drive and use machines

Betagan has minor influence on the ability to drive and use machines. Betagan may cause transient blurring of vision, fatigue and/or drowsiness which may impair the ability to drive or operate machines. The patient should wait until these symptoms have cleared before driving or using machinery.

4.8 Undesirable effects

Like other topically applied ophthalmic drugs, levobunolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta-blocking agents. Incidence of systemic ADRs after topical ophthalmic administration of beta-blocking agents is lower than for systemic administration

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following terminologies have been used in order to classify the occurrence of undesirable effects: Very Common (>1/10); Common (>1/100 to <1/10); Uncommon (>1/1,000 to <1/100); Rare (>1/10,000 to <1/1,000); Very rare (<1/10,000), not known (cannot be estimated from the available data).

Psychiatric Disorders

Not known: Depression

Nervous System Disorders

Not known: Confusion, Dizziness, Somnolence, Lethargy, Headache,

Insomnia

Eye Disorders

Very Common: Eye irritation, Eye painCommon: Blepharitis, Conjunctivitis Not known: Conjunctival/Ocular hyperemia, Conjuctivitis allergic, Corneal reflex decreased, Iridocyclitis, Keratitis, Vision blurred, Punctate keratitis, Eye/Eyelids pruritus, Eye/Eyelid oedema, Eye discharge, Lacrimation increased, Dry eye

Cardiac Disorders

Not known: Syncope, Bradycardia, Atrioventricular block, Palpitations Vascular Disorders

Not known: Hypotension, Raynaud’s phenomenon

Respiratory, Thoracic, and Mediastinal Disorders

Not known: Asthma, Dyspnoea, Throat irritation, Nasal discomfort

Gastrointestinal Disorders

Not known: Nausea

Skin and Subcutaneous Tissue Disorders

Not known: Urticaria, Dermatitis contact (including allergic contact dermatitis), Rash, Erythema of eyelid, Eyelid eczema, Skin exfoliation, Lichenoid keratosis, Pruritus

General Disorders and Administration Site Conditions

Not known: Face oedema, Fatigue/asthenia

Additional adverse reactions have been seen with other ophthalmic beta-blockers and may potentially occur with Betagan:

Eye Disorders: Choroidal detachment following filtration surgery, Corneal erosion, Diplopia, Ptosis

Immune System Disorders: Anaphylactic reaction, Systemic allergic reactions including angioedema

Metabolism and Nutrition Disorders: Hypoglycaemia Psychiatric disorders: Memory loss, Nightmares

Nervous System Disorders: Cerebral ischemia, Cerebrovascular accident, Increases in signs and symptoms of myasthenia gravis, Paraesthesia

Cardiac Disorders: Arrhythmia, Cardiac arrest, Cardiac failure, Chest pain, Congestive heart failure, Oedema

Vascular disorders: Cold hands and feet

Respiratory, Thoracic, and Mediastinal Disorders: Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), Cough

Gastrointestinal Disorders: Abdominal pain, Diarrhoea, Dysgeusia, Dry mouth, Dyspepsia, vomiting

Skin and Subcutaneous Tissue Disorders: Alopecia, Psoriasiform rash or exacerbation of psoriasis

Musculoskeletal and Connective Tissue Disorders: Myalgia

Reproductive System and Breast Disorders: Decreased libido, Sexual dysfunction

Adverse reactions reported in eye drops containing phosphates:

Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard.

4.9 Overdose

There are no data available on human overdosage with Betagan which is unlikely to occur via the ocular route. Should accidental ocular overdosage occur, flush the eye(s) with water or normal saline. If accidentally ingested, systemic symptoms may result and efforts to decrease further absorption may be appropriate. The symptoms associated with systemic overdosage are most likely to be bradycardia, hypotension, bronchospasm and cardiac failure. Therapy for overdosage of a beta-adrenergic agent should be instituted, such as intravenous administration of atropine sulfate 0.25 to 2 mg to induce vagal blockade. Conventional therapy for hypotension, bronchospasm, heart block and cardiac failure may be necessary.

5    PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Beta blocking agents

ATC code: S01ED 03

5.1    Pharmacodynamic properties

Safety and effectiveness of Betagan in paediatric patients have not been established.

Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity. In order to obtain the highest degree of beta-blocking potential without increasing the potential for direct myocardial depression, the levo isomer, levobunolol, is used. Levobunolol does not have significant local anaesthetic (membrane-stabilising) or intrinsic sympathomimetic activity. Betagan has shown to be as effective as Timolol in lowering intraocular pressure.

Betagan when instilled in the eye will lower elevated intraocular pressure as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure presents a major risk factor in the pathogenesis of glaucomatous field loss. The higher the level of intraocular pressure, the likelihood of optic nerve damage and visual field loss.

The primary mechanism of action of levobunolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. Betagan reduces intraocular pressure with little or no effect on pupil size in contrast to the miosis which cholinergic agents are known to produce.

The blurred vision and night blindness often associated with miotics would not be expected with the use of Betagan. Patients with cataracts avoid the inability to see around lenticular opacities caused by pupil constriction.

5.2    Pharmacokinetic properties

The onset of action with one drop of Betagan can be detected within one hour after instillation, with maximum effect seen between two and six hours. A significant decrease can be maintained for up to 24 hours following a single dose.

5.3    Preclinical safety data

Not applicable.

6    PHARMACEUTICAL PARTICULARS

6.1    List of excipients

Poly (vinyl alcohol)

Sodium chloride Disodium edetate

Sodium phosphate dibasic, heptahydrate Potassium phosphate monobasic

Sodium hydroxide (to adjust pH) or hydrochloric acid (to adjust pH)

Purified water

6.2    Incompatibilities

No major incompatibilities have been reported from topical use of levobunolol.

6.3 Shelf life

18 months.

The eye drop solution should be used immediately after opening. Any unused solution should be discarded.

6.4    Special precautions for storage

Do not store above 25°C.

Keep the bottle in the outer carton in order to protect from light.

6.5 Nature and contents of container

Low density polyethylene (LDPE) blow-fill-seal unit dose container (0.9 ml volume) filled with 0.4 ml solution.

Unit dose containers are packaged into a foil covered pouch (5 containers per pouch).

Pouches are packaged into cartons such that each carton contains 30 or 60 unit dose containers.

6.6 Special precautions for disposal and other handling

Ensure that the single dose container is intact before use. Discard any unused solution (i.e. once opened do not re-use container for subsequent doses).

7 MARKETING AUTHORISATION HOLDER

Allergan Limited Marlow International The Parkway Marlow

Buckinghamshire, SL7 1YL United Kingdom

8    MARKETING AUTHORISATION NUMBER(S)

PL 00426/0072

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

20/04/1993 / 25/07/2003

10 DATE OF REVISION OF THE TEXT

30/09/2014